EP
SUPN icon

Essential Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Essential Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21K Buy
112
+26
+30% +$1.25K ﹤0.01% 1526
2026
Q1 		$4.45K Hold
86
– – ﹤0.01% 1632
2025
Q4 		$4.27K Hold
86
– – ﹤0.01% 1492
2025
Q3 		$4.11K Buy
86
+25
+41% +$1.01K ﹤0.01% 1500
2025
Q2 		$1.92K Buy
+61
New +$1.96K ﹤0.01% 1330

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Essential Partners's SUPN Position: Q2 2026 in Review

Essential Partners increased its Supernus Pharmaceuticals (SUPN) stake by 30% in Q2 2026, buying an estimated $1.25K and bringing the position to 112 shares worth $5.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Essential Partners first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Essential Partners held 112 shares of Supernus Pharmaceuticals worth $5.21K as of Q2 2026.
  • Essential Partners bought 26 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.25K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1526 holding.
  • Essential Partners first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.